Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dihydroergotamine mesilate intranasal - Britannia

Next Previous
X
Search
Drug Profile

Dihydroergotamine mesilate intranasal - Britannia

Alternative Names: Dihydroergotamine nasal powder - Britannia

Latest Information Update: 15 Oct 2020

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Britannia Pharmaceuticals
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Migraine

Most Recent Events

  • 02 Oct 2020 Britannia Pharmaceuticals has been acquired by STADA Arzneimittel
  • 30 May 2007 Dihydroergotamine-intranasal is still in phase I trials for migraine in the EU
  • 06 Apr 2004 Dihydroergotamine nasal powder for migraine is available for licensing worldwide (http://www.britannia-pharm.co.uk)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top